<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27746192</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>293</EndPage><MedlinePgn>284-293</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2016.10.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(16)30461-3</ELocationID><Abstract><AbstractText>Infection with one of the four dengue virus serotypes (DENV1-4) presumably leads to lifelong immunity against the infecting serotype but not against heterotypic reinfection, resulting in a greater risk of developing Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) during secondary infection. Both antibodies and T cell responses have been implicated in DHF/DSS pathogenesis. According to the T cell-based hypothesis termed "original antigenic sin," secondary DENV infection is dominated by non-protective, cross-reactive T cells that elicit an aberrant immune response. The goal of our study was to compare the roles of serotype-specific and cross-reactive T cells in protection vs. pathogenesis during DENV infection in vivo. Specifically, we utilized IFN-&#x3b1;/&#x3b2;R<sup>-/-</sup> HLA*B0702 transgenic mice in the context of peptide vaccination with relevant human CD8 T cell epitopes. IFN-&#x3b1;/&#x3b2;R<sup>-/-</sup> HLA*B0702 transgenic mice were immunized with DENV serotype 2 (DENV2)-specific epitopes or variants found in any of the other three serotypes (DENV1, DENV3 or DENV4), followed by challenge with DENV. Although cross-reactive T cell responses were lower than responses elicited by serotype-specific T cells, immunization with either serotype-specific or variant peptide epitopes enhanced viral clearance, demonstrating that both serotype-specific and cross-reactive T cells can contribute to protection in vivo against DENV infection.</AbstractText><CopyrightInformation>Copyright &#xc2;&#xa9; 2016 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elong Ngono</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hui-Wen</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, National Taiwan University, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Yunichel</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiskopf</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidney</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sette</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shresta</LastName><ForeName>Sujan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States. Electronic address: sujan@lji.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI116813</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI085063</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI082185</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AI057157</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015235">HLA-B Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016056">Immunodominant Epitopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015235" MajorTopicYN="N">HLA-B Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016056" MajorTopicYN="N">Immunodominant Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cross-reactivity</Keyword><Keyword MajorTopicYN="N">Dengue</Keyword><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27746192</ArticleId><ArticleId IdType="pmc">PMC5264312</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2016.10.006</ArticleId><ArticleId IdType="pii">S2352-3964(16)30461-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguirre S., Maestre A.M., Pagni S., Patel J.R., Savage T., Gutman D., Maringer K. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog. 2012;8(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464218</ArticleId><ArticleId IdType="pubmed">23055924</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods. 2004;294(1&#x2013;2):15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15604012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashour J., Morrison J., Laurent-Rolle M., Belicha-Villanueva A., Plumlee C.R., Bernal-Rubio D., Williams K.L. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe. 2010;8(5):410&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310429</ArticleId><ArticleId IdType="pubmed">21075352</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsitis S.J., Williams K.L., Lachica R., Flores D., Kyle J.L., Mehlhop E., Johnson S., Diamond M.S., Robert Beatty P., Harris E. Lethal antibody enhancement of dengue disease in mice is prevented by fc modification. PLoS Pathog. 2010;6(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820409</ArticleId><ArticleId IdType="pubmed">20168989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashyam H.S., Green S., Rothman A.L. Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J. Immunol. (Baltimore, Md.: 1950) 2006;176(5):2817&#x2013;2824.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493038</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., Drake J.M. The global distribution and burden of dengue. Nature. 2013;496(7446):504&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H., George S.L., Stinchcomb D.T., Osorio J.E., Partidos C.D. CD8+ T-cell responses in Flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate. J. Infect. Dis. 2015;212(10):1618&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4621245</ArticleId><ArticleId IdType="pubmed">25943203</ArticleId></ArticleIdList></Reference><Reference><Citation>de Matos A.M., Carvalho K.I., Rosa D.S., Villas-Boas L.S., da Silva W.C., de Lima Rodrigues C.L., Oliveira O.M.N.P.F. CD8+ T lymphocyte expansion, proliferation and activation in dengue fever. PLoS Negl. Trop. Dis. 2015;9(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326415</ArticleId><ArticleId IdType="pubmed">25675375</ArticleId></ArticleIdList></Reference><Reference><Citation>Duangchinda T., Dejnirattisai W., Vasanawathana S., Limpitikul W., Tangthawornchaikul N., Malasit P., Mongkolsapaya J., Screaton G. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc. Natl. Acad. Sci. U. S. A. 2010;107(39):16922&#x2013;16927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947904</ArticleId><ArticleId IdType="pubmed">20837518</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B., Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat. Rev. Microbiol. 2016;14(1):45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26639777</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B., Briand O., Lang J., Saville M., Jackson N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine. 2015;33(50):7100&#x2013;7111.</Citation><ArticleIdList><ArticleId IdType="pubmed">26475445</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., Hunsperger E. Dengue: a continuing global threat. Nat. Rev. Microbiol. 2010;8(12 Suppl):S7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333201</ArticleId><ArticleId IdType="pubmed">21079655</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadinegoro S.R., Arredondo-Garc&#xed;a J.L., Capeding M.R., Deseda C., Chotpitayasunondh T., Reynaldo D., Ismail H.I.H.M. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 2015;373(13):1195&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pubmed">26214039</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead S.B. Dengue. Lancet (London, England) 2007;370(9599):1644&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17993365</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead S.B. Controversies in dengue pathogenesis. Paediatr. Int. Child Health. 2012;32(Suppl 1):5&#x2013;9. (May)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381449</ArticleId><ArticleId IdType="pubmed">22668442</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead S.B., Russell P.K. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016 (February)</Citation><ArticleIdList><ArticleId IdType="pubmed">26873054</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaratne S.D., Atukorale V., Gomes L., Chang T., Wijesinghe T., Fernando S., Ogg G.S., Malavige G.N. Evaluation of the WHO revised criteria for classification of clinical disease severity in acute adult dengue infection. BMC Res. Notes. 2012;5:645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534490</ArticleId><ArticleId IdType="pubmed">23167997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno G., Chang G.J., Tsuchiya K.R., Karabatsos N., Cropp C.B. Phylogeny of the genus Flavivirus. J. Virol. 1998;72(1):73&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109351</ArticleId><ArticleId IdType="pubmed">9420202</ArticleId></ArticleIdList></Reference><Reference><Citation>Low J.G.H., Ooi E.-E., Tolfvenstam T., Leo Y.-S., Hibberd M.L., Ng L.-C., Lai Y.-L. Early dengue infection and outcome study (EDEN) &#x2014; study design and preliminary findings. Ann. Acad. Med. Singap. 2006;35(11):783&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pubmed">17160194</ArticleId></ArticleIdList></Reference><Reference><Citation>Malavige G.N., Ogg G. Pathogenesis of severe dengue infection. Ceylon Med. J. 2012;57(3):97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">23086023</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangada M.M., Rothman A.L. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J. Immunol. (Baltimore, Md.: 1950) 2005;175(4):2676&#x2013;2683.</Citation><ArticleIdList><ArticleId IdType="pubmed">16081844</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongkolsapaya J., Dejnirattisai W., Xu X.-n., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., Sawasdivorn S. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 2003;9(7):921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808447</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongkolsapaya J., Duangchinda T., Dejnirattisai W., Vasanawathana S., Avirutnan P., Jairungsri A., Khemnu N. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol. (Baltimore, Md.: 1950) 2006;176(6):3821&#x2013;3829.</Citation><ArticleIdList><ArticleId IdType="pubmed">16517753</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry S.T., Prestwood T.R., Lada S.M., Benedict C.A., Shresta S. Cardif-mediated signaling controls the initial innate response to dengue virus in vivo. J. Virol. 2009;83(16):8276&#x2013;8281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715757</ArticleId><ArticleId IdType="pubmed">19494017</ArticleId></ArticleIdList></Reference><Reference><Citation>Prestwood T.R., Morar M.M., Zellweger R.M., Miller R., May M.M., Yauch L.E., Lada S.M., Shresta S. Gamma interferon (IFN-&#x3b3;) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-&#x3b1;/&#x3b2; receptor-deficient mice. J. Virol. 2012;86(23):12561&#x2013;12570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3497655</ArticleId><ArticleId IdType="pubmed">22973027</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman A.L., Medin C.L., Friberg H., Currier J.R. Immunopathogenesis versus protection in dengue virus infections. Curr. Trop. Med. Rep. 2014;1(1):13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036645</ArticleId><ArticleId IdType="pubmed">24883262</ArticleId></ArticleIdList></Reference><Reference><Citation>Screaton G., Mongkolsapaya J., Yacoub S., Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 2015;15(12):745&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">26603900</ArticleId></ArticleIdList></Reference><Reference><Citation>Shresta S., Sharar K.L., Prigozhin D.M., Robert Beatty P., Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 2006;80(20):10208&#x2013;10217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1617308</ArticleId><ArticleId IdType="pubmed">17005698</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidney J., Southwood S., Moore C., Oseroff C., Pinilla C., Grey H.M., Sette A. Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. In: Coligan J.E., editor. Current Protocols in Immunology. 2013. Chapter 18 (February): Unit 18.3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3626435</ArticleId><ArticleId IdType="pubmed">23392640</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons C.P., Dong T., Chau N.V., Dung N.T.P., Chau T.N.B., Thao L.T.T., Dung N.T., Hien T.T., Rowland-Jones S., Farrar J. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J. Virol. 2005;79(9):5665&#x2013;5675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1082776</ArticleId><ArticleId IdType="pubmed">15827181</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Yauch L.E., Angelo M.A., John D.V., Greenbaum J.A., Sidney J., Kolla R.V. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J. Immunol. (Baltimore, Md.: 1950) 2011;187(8):4268&#x2013;4279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3186824</ArticleId><ArticleId IdType="pubmed">21918184</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Angelo M.A., de Azeredo E.L., Sidney J., Greenbaum J.A., Fernando A.N., Broadwater A. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 2013;110(22):E2046&#x2013;E2053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3670335</ArticleId><ArticleId IdType="pubmed">23580623</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Angelo M.A., Sidney J., Peters B., Shresta S., Sette A. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J. Virol. 2014;88(19):11383&#x2013;11394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178794</ArticleId><ArticleId IdType="pubmed">25056881</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Bangs D.J., Sidney J., Kolla R.V., De Silva A.D., de Silva A.M., Crotty S., Peters B., Sette A. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc. Natl. Acad. Sci. U. S. A. 2015;112(31):E4256&#x2013;E4263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4534238</ArticleId><ArticleId IdType="pubmed">26195744</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Cerpas C., Angelo M.A., Bangs D.J., Sidney J., Paul S., Peters B. Human CD8+ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J. Infect. Dis. 2015;212(11):1743&#x2013;1751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4633759</ArticleId><ArticleId IdType="pubmed">25980035</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Angelo M.A., Bangs D.J., Sidney J., Paul S., Peters B., de Silva A.D. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J. Virol. 2015;89(1):120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301095</ArticleId><ArticleId IdType="pubmed">25320311</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch L.E., Zellweger R.M., Kotturi M.F., Qutubuddin A., Sidney J., Peters B., Prestwood T.R., Sette A., Shresta S. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. (Baltimore, Md.: 1950) 2009;182(8):4865&#x2013;4873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674070</ArticleId><ArticleId IdType="pubmed">19342665</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch L.E., Prestwood T.R., May M.M., Morar M.M., Zellweger R.M., Peters B., Sette A., Shresta S. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J. Immunol. (Baltimore, Md.: 1950) 2010;185(9):5405&#x2013;5416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962919</ArticleId><ArticleId IdType="pubmed">20870934</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.-Y., Chang T.-H., Liang J.-J., Chiang R.-L., Lee Y.-L., Liao C.-L., Lin Y.-L. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog. 2012;8(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3386177</ArticleId><ArticleId IdType="pubmed">22761576</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger R.M., Prestwood T.R., Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe. 2010;7(2):128&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824513</ArticleId><ArticleId IdType="pubmed">20153282</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger R.M., Miller R., Eddy W.E., White L.J., Johnston R.E., Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. 2013;9(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814346</ArticleId><ArticleId IdType="pubmed">24204271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger R.M., Eddy W.E., Tang W.W., Miller R., Shresta S. CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J. Immunol. (Baltimore, Md.: 1950) 2014;193(8):4117&#x2013;4124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185219</ArticleId><ArticleId IdType="pubmed">25217165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger R.M., Tang W.W., Eddy W.E., King K., Sanchez M.C., Shresta S. CD8+ T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J. Virol. 2015;89(12):6494&#x2013;6505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4474296</ArticleId><ArticleId IdType="pubmed">25855749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>